JPH08502028A - インターロイキン−6を含有する薬剤組成物、及び消耗性凝血出血疾患の治療への該薬剤組成物の使用 - Google Patents
インターロイキン−6を含有する薬剤組成物、及び消耗性凝血出血疾患の治療への該薬剤組成物の使用Info
- Publication number
- JPH08502028A JPH08502028A JP6502970A JP50297094A JPH08502028A JP H08502028 A JPH08502028 A JP H08502028A JP 6502970 A JP6502970 A JP 6502970A JP 50297094 A JP50297094 A JP 50297094A JP H08502028 A JPH08502028 A JP H08502028A
- Authority
- JP
- Japan
- Prior art keywords
- interleukin
- hemorrhagic
- treatment
- coagulation
- wasting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.消耗性凝血出血疾患の治療或いは予防用薬剤の製造へのインターロイキン− 6の使用。 2.前記凝血出血疾患は汎発性血管内凝固症候群である、請求項1記載の使用。 3.少なくとも1つの急性相蛋白質のレベル低下に関連する機能障害の治療或い は予防用薬剤へのインターロイキン−6の使用。 4.前記疾患或いは機能障害は、代償汎発性血管内凝固症候群、脱線維素症候群 、一次線維素溶解或いは細小血管障害血小板減少症である、請求項1乃至3の何 れかに記載の使用。 5.前記消耗性凝血出血疾患は、組織要素の遊離、内皮損傷、脈管奇形及び感染 により生じてなる、請求項1乃至4の何れかに記載の使用。 6.前記感染は敗血性ショックを伴う、請求項5記載の使用。 7.前記薬剤は投与量分のユニットに分けた形態を成し、各ユニットは一投与分 として35乃至350μgのインターロイキン−6を含む、請求項1乃至6記載 の使用。 8.消耗性凝血出血疾患にかかった、或いはかかる危険性のある人間或いは動物 の患者に、有効量のインターロイキン−6を投与してなる、治療或いは予防方法 。 9.体重1kgにつき1日当たり0.5乃至30μgのインターロイキン−6を 静脈から投与してなる、請求項8記載の方法。 10.インターロイキン−6を、体重1kgにつき1時間当たり0.02乃至1 .25μgを非径口にて或いは放出を遅らせる形態で投与してなる、請求項8記 載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929214489A GB9214489D0 (en) | 1992-07-08 | 1992-07-08 | Pharmaceutical compositions and uses therefor |
GB9214489.8 | 1992-07-08 | ||
GB939301251A GB9301251D0 (en) | 1993-01-22 | 1993-01-22 | Pharmaceutical compositions and use therefor |
GB9301251.6 | 1993-01-22 | ||
PCT/EP1993/001790 WO1994001123A1 (en) | 1992-07-08 | 1993-07-08 | Pharmaceutical composition containing il-6, their uses for the treatment of consumptive thrombo-hemorrhagic disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08502028A true JPH08502028A (ja) | 1996-03-05 |
JP3845112B2 JP3845112B2 (ja) | 2006-11-15 |
Family
ID=26301225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50297094A Expired - Fee Related JP3845112B2 (ja) | 1992-07-08 | 1993-07-08 | インターロイキン−6を含有する薬剤組成物、及び消耗性凝血出血疾患の治療への該薬剤組成物の使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5925344A (ja) |
EP (1) | EP0651648B1 (ja) |
JP (1) | JP3845112B2 (ja) |
AT (1) | ATE228848T1 (ja) |
AU (1) | AU674864B2 (ja) |
CA (1) | CA2139353C (ja) |
DE (1) | DE69332541T2 (ja) |
DK (1) | DK0651648T3 (ja) |
ES (1) | ES2183814T3 (ja) |
IL (1) | IL106272A (ja) |
MX (1) | MX9304075A (ja) |
PT (1) | PT651648E (ja) |
WO (1) | WO1994001123A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015063567A (ja) * | 2009-10-16 | 2015-04-09 | オメロス コーポレーション | Masp−2依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法 |
US10059776B2 (en) | 2011-04-08 | 2018-08-28 | Omerus Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7108982B1 (en) | 1999-02-19 | 2006-09-19 | University Of Iowa Research Foundation | Diagnostics and the therapeutics for macular degeneration |
AU3704500A (en) * | 1999-02-19 | 2001-01-22 | University Of Iowa Research Foundation, The | Diagnostics and therapeutics for arterial wall disruptive disorders |
EP1066834A3 (de) * | 1999-07-08 | 2004-06-02 | Thomas Dr. Stief | Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens |
WO2002015882A1 (en) * | 2000-08-24 | 2002-02-28 | Lytone Enterprise, Inc. | Delayed release compositions and combinations |
FI20041425A0 (fi) * | 2004-11-05 | 2004-11-05 | Orion Corp | Transmukosaalinen veterinäärinen koostumus |
RU2477530C2 (ru) * | 2011-04-28 | 2013-03-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к интерлейкину-6 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5271931A (en) * | 1988-09-14 | 1993-12-21 | The Scripps Research Institute | Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6 |
JPH0372429A (ja) * | 1988-10-07 | 1991-03-27 | Chugai Pharmaceut Co Ltd | 血小板減少症の治療剤 |
JP2805224B2 (ja) * | 1989-01-13 | 1998-09-30 | 味の素株式会社 | 血小板減少症治療剤 |
US5087448A (en) * | 1989-02-02 | 1992-02-11 | The Board Of Regents Of The University Of Oklahoma | Enhancing growth of megakaryocytes in mammals using interleuking 6 |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
US5188828A (en) * | 1990-11-08 | 1993-02-23 | Brigham And Women's Hospital | Interleukin-6 to stimulate erythropoietin production |
AU9059991A (en) * | 1990-11-13 | 1992-06-11 | Children's Medical Center Corporation | Controlling beta-amyloid related neuronal degeneration by antagonizing NGF-effected neuronal activity |
EP0560998A4 (en) * | 1991-10-09 | 1993-12-01 | Toray Industries, Inc. | Medicine for preventing and treating bleeding tendency |
-
1993
- 1993-07-07 MX MX9304075A patent/MX9304075A/es not_active IP Right Cessation
- 1993-07-08 DE DE69332541T patent/DE69332541T2/de not_active Expired - Fee Related
- 1993-07-08 WO PCT/EP1993/001790 patent/WO1994001123A1/en active IP Right Grant
- 1993-07-08 IL IL10627293A patent/IL106272A/en not_active IP Right Cessation
- 1993-07-08 CA CA002139353A patent/CA2139353C/en not_active Expired - Fee Related
- 1993-07-08 PT PT93915854T patent/PT651648E/pt unknown
- 1993-07-08 DK DK93915854T patent/DK0651648T3/da active
- 1993-07-08 ES ES93915854T patent/ES2183814T3/es not_active Expired - Lifetime
- 1993-07-08 JP JP50297094A patent/JP3845112B2/ja not_active Expired - Fee Related
- 1993-07-08 AU AU45664/93A patent/AU674864B2/en not_active Ceased
- 1993-07-08 US US08/367,124 patent/US5925344A/en not_active Expired - Fee Related
- 1993-07-08 AT AT93915854T patent/ATE228848T1/de not_active IP Right Cessation
- 1993-07-08 EP EP93915854A patent/EP0651648B1/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015063567A (ja) * | 2009-10-16 | 2015-04-09 | オメロス コーポレーション | Masp−2依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法 |
US10059776B2 (en) | 2011-04-08 | 2018-08-28 | Omerus Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
Also Published As
Publication number | Publication date |
---|---|
MX9304075A (es) | 1994-04-29 |
CA2139353C (en) | 2006-11-07 |
IL106272A0 (en) | 1993-11-15 |
DK0651648T3 (da) | 2003-01-06 |
AU674864B2 (en) | 1997-01-16 |
US5925344A (en) | 1999-07-20 |
ES2183814T3 (es) | 2003-04-01 |
JP3845112B2 (ja) | 2006-11-15 |
EP0651648A1 (en) | 1995-05-10 |
PT651648E (pt) | 2003-04-30 |
DE69332541D1 (de) | 2003-01-16 |
ATE228848T1 (de) | 2002-12-15 |
DE69332541T2 (de) | 2003-04-17 |
IL106272A (en) | 1999-01-26 |
AU4566493A (en) | 1994-01-31 |
CA2139353A1 (en) | 1994-01-20 |
EP0651648B1 (en) | 2002-12-04 |
WO1994001123A1 (en) | 1994-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1186994A (en) | Therapeutic method and method for making compositions for use therein | |
DE60115422T2 (de) | PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR | |
TWI225404B (en) | Pharmaceutical composition for treating hypercoagulable states or acquired protein C deficiency | |
Avvisati et al. | Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia | |
Kwaan et al. | A study of pancreatic enzymes as a factor in the pathogenesis of disseminated intravascular coagulation during acute pancreatitis | |
Innerfield et al. | Intravenous trypsin: its anticoagulant, fibrinolytic and thrombolytic effects | |
White et al. | Toxicity of human hemoglobin solution infused into rabbits | |
Berrettini et al. | Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency | |
Monagle et al. | Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin | |
Abildgaard et al. | Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors | |
Liebman et al. | Increased fibrinolysis and amyloidosis | |
WO2008135963A2 (en) | Fibrinogen for treatment of bleeding in trauma and platelet disorders | |
Bachmann | Disseminated intravascular coagulation | |
Hampton et al. | Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate | |
JPH08502028A (ja) | インターロイキン−6を含有する薬剤組成物、及び消耗性凝血出血疾患の治療への該薬剤組成物の使用 | |
Cacciola et al. | Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia: a pilot study | |
KR20060126762A (ko) | 외상의 말기 합병증을 치료하기 위한 인자 ⅴⅰⅰa의 용도 | |
KR20040094288A (ko) | Ards의 치료에 있어 변형된 fⅶ | |
Locht et al. | Severe skin necrosis following warfarin therapy in a patient with protein C deficiency | |
Jeljaszewicz et al. | Intravascular Coagulation and Fibrinolysis by Stapliylocoagiilase. Comparison with Thrombin | |
Brodsky et al. | Pulmonary embolism with factor XI deficiency | |
Gomperts, ED & Demetrious | Laboratory studies and clinical features in a case of boomslang envenomation | |
Leaker et al. | Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation | |
Niklasson et al. | Thrombocytopenia and bleeding complications in severe cases of meningococcal infection treated with heparin, dextran 70 and chlorpromazine | |
CN1071578C (zh) | 药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040511 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040730 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050413 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050725 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060818 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |